MX2019003544A - Composiciones que comprenden un ligando de union al receptor cannabinoide. - Google Patents

Composiciones que comprenden un ligando de union al receptor cannabinoide.

Info

Publication number
MX2019003544A
MX2019003544A MX2019003544A MX2019003544A MX2019003544A MX 2019003544 A MX2019003544 A MX 2019003544A MX 2019003544 A MX2019003544 A MX 2019003544A MX 2019003544 A MX2019003544 A MX 2019003544A MX 2019003544 A MX2019003544 A MX 2019003544A
Authority
MX
Mexico
Prior art keywords
receptor binding
binding ligand
cannabinoid receptor
compositions
medicament
Prior art date
Application number
MX2019003544A
Other languages
English (en)
Spanish (es)
Inventor
Günther Bernhard
Löscher Frank
Krösser Sonja
Steven Philipp
Original Assignee
Novaliq Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novaliq Gmbh filed Critical Novaliq Gmbh
Publication of MX2019003544A publication Critical patent/MX2019003544A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2019003544A 2016-09-28 2017-09-27 Composiciones que comprenden un ligando de union al receptor cannabinoide. MX2019003544A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16191194 2016-09-28
EP17168172 2017-04-26
PCT/EP2017/074545 WO2018060282A1 (en) 2016-09-28 2017-09-27 Compositions comprising a cannabinoid receptor binding ligand

Publications (1)

Publication Number Publication Date
MX2019003544A true MX2019003544A (es) 2019-09-19

Family

ID=59966776

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003544A MX2019003544A (es) 2016-09-28 2017-09-27 Composiciones que comprenden un ligando de union al receptor cannabinoide.

Country Status (10)

Country Link
US (1) US20190343793A1 (cg-RX-API-DMAC7.html)
EP (2) EP3518921B1 (cg-RX-API-DMAC7.html)
JP (1) JP2019534867A (cg-RX-API-DMAC7.html)
KR (1) KR20190060787A (cg-RX-API-DMAC7.html)
CN (1) CN109803650A (cg-RX-API-DMAC7.html)
AU (1) AU2017333420A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019006194A2 (cg-RX-API-DMAC7.html)
CA (1) CA3036313A1 (cg-RX-API-DMAC7.html)
MX (1) MX2019003544A (cg-RX-API-DMAC7.html)
WO (1) WO2018060282A1 (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2564502T3 (es) 2010-03-17 2016-03-23 Novaliq Gmbh Composición farmacéutica para el tratamiento de la presión intraocular aumentada
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
CN113679699B (zh) 2012-09-12 2022-10-28 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
WO2014041071A1 (en) 2012-09-12 2014-03-20 Novaliq Gmbh Semifluorinated alkane compositions
DK3024484T3 (en) 2013-07-23 2018-10-08 Novaliq Gmbh STABILIZED ANTIBODY COMPOSITIONS
KR102584063B1 (ko) 2015-09-30 2023-09-27 노바리크 게엠베하 부분불소화 화합물
CN110403923B (zh) 2015-09-30 2021-09-21 诺瓦利克有限责任公司 半氟化化合物和其组合物
JP6774508B2 (ja) 2016-05-03 2020-10-28 ニューマ・リスパイラトリー・インコーポレイテッド 流体を肺系に供給するための液滴送達装置、及びその使用方法
KR102257916B1 (ko) 2016-06-23 2021-05-28 노바리크 게엠베하 드롭 디스펜서를 포함하는 키트
MX2019003363A (es) 2016-09-22 2019-10-02 Novaliq Gmbh Composiciones farmaceuticas para usarse en la terapia de la blefaritis.
ES2965677T3 (es) 2016-09-23 2024-04-16 Novaliq Gmbh Composiciones oftálmicas que comprenden ciclosporina
US10732712B2 (en) * 2016-12-27 2020-08-04 Facebook Technologies, Llc Large scale integration of haptic devices
AU2018253944B2 (en) 2017-04-21 2022-09-15 Dermaliq Therapeutics, Inc. Iodine compositions
EP3621601A1 (en) 2017-05-12 2020-03-18 Novaliq GmbH Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions
MX2020003534A (es) 2017-09-27 2020-07-29 Novaliq Gmbh Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares.
CN111182893A (zh) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
WO2019071008A1 (en) 2017-10-04 2019-04-11 Pneuma Respiratory, Inc. ELECTRONIC DEVICE FOR DELIVERY OF LINEAR SHAPE ADMINISTRATION OPERATED BY BREATHING AND METHODS OF USE
US11771852B2 (en) 2017-11-08 2023-10-03 Pneuma Respiratory, Inc. Electronic breath actuated in-line droplet delivery device with small volume ampoule and methods of use
BR112020017838A2 (pt) 2018-03-02 2020-12-22 Novaliq Gmbh Composições farmacêuticas que compreendem nebivolol
JP2021522219A (ja) 2018-04-27 2021-08-30 ノバリック ゲーエムベーハー 緑内障の治療のためのタフルプロストを含む眼科用組成物
EP4406533A3 (en) 2018-10-12 2024-10-09 Novaliq GmbH Ophthalmic composition for treatment of dry eye disease
CN113614078A (zh) * 2019-02-01 2021-11-05 爱瑞制药公司 用于治疗近视的化合物、组合物和方法
US12397039B2 (en) 2019-02-13 2025-08-26 Novaliq Gmbh Compositions and methods for the treatment of ocular neovascularization
EP4025235A1 (en) 2019-09-06 2022-07-13 Novaliq GmbH Ophthalmic composition for the treatment of uveitis
AU2021347760B2 (en) * 2020-09-24 2024-07-25 Nicoventures Trading Limited Formulation
CN116940349A (zh) * 2020-10-05 2023-10-24 麦氏生物科技有限公司 含大麻素的组合物以及用于治疗和预防疾病的用途
US11191751B1 (en) * 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions
EP4288151A4 (en) 2021-02-03 2025-01-01 ADS Therapeutics LLC Topical ophthalmological compositions
US11793945B2 (en) 2021-06-22 2023-10-24 Pneuma Respiratory, Inc. Droplet delivery device with push ejection
US20250228876A1 (en) * 2021-10-13 2025-07-17 Pneuma Respiratory, Inc. Compositions for delivery of cannabinoids
WO2024020041A1 (en) 2022-07-18 2024-01-25 Pneuma Respiratory, Inc. Small step size and high resolution aerosol generation system and method

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19536504C2 (de) * 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
CN101516333A (zh) 2006-08-04 2009-08-26 英西斯治疗学股份有限公司 水性屈大麻酚制剂
US8222292B2 (en) 2007-08-06 2012-07-17 Insys Therapeutics, Inc. Liquid cannabinoid formulations
CA2741862C (en) 2008-10-31 2017-10-17 Mahmoud A. Elsohly Compositions containing delta-9-thc-amino acid esters and process of preparation
AT509000B1 (de) * 2009-10-23 2012-12-15 Rausch Peter Wasserlösliche zubereitungen von cannabinoiden und cannabispräparaten und deren anwendungen
EP2335735A1 (en) * 2009-12-14 2011-06-22 Novaliq GmbH Pharmaceutical composition for treatment of dry eye syndrome
EP2444063A1 (en) * 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
US8758826B2 (en) 2011-07-05 2014-06-24 Wet Inc. Cannabinoid receptor binding agents, compositions, and methods
WO2014041071A1 (en) * 2012-09-12 2014-03-20 Novaliq Gmbh Semifluorinated alkane compositions
CN113679699B (zh) * 2012-09-12 2022-10-28 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
CN106061490A (zh) 2013-10-09 2016-10-26 列奥尼达斯·A·约翰逊 一种治疗和预防眼部疾病症状或体征的方法及组合物
WO2015074137A1 (en) 2013-11-20 2015-05-28 Mary Lynch Compositions and methods for treatment of ocular inflammation and pain
MA41299A (fr) * 2014-12-30 2017-11-07 Axim Biotechnologies Inc Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite

Also Published As

Publication number Publication date
CA3036313A1 (en) 2018-04-05
EP3518921B1 (en) 2021-08-11
WO2018060282A1 (en) 2018-04-05
US20190343793A1 (en) 2019-11-14
JP2019534867A (ja) 2019-12-05
CN109803650A (zh) 2019-05-24
BR112019006194A2 (pt) 2019-06-18
EP3518921A1 (en) 2019-08-07
EP3698785A1 (en) 2020-08-26
AU2017333420A1 (en) 2019-04-04
KR20190060787A (ko) 2019-06-03

Similar Documents

Publication Publication Date Title
MX2019003544A (es) Composiciones que comprenden un ligando de union al receptor cannabinoide.
MX2022010168A (es) Moduladores de calpainas y usos terapeuticos de los mismos.
HK1255162A1 (zh) 爱帕琳肽受体激动剂及使用方法
MX2018005340A (es) Proteolisis de direccionamiento a compuestos de quimera y metodos de preparacion y uso de los mismos.
PH12015502621A1 (en) Estrogen receptor modulator and uses thereof
MY195244A (en) Muscarinic Agonists
EP3957723A3 (en) Engineered ligase variants
MX2015016171A (es) Moduladores del receptor de estrogeno de azetidina y usos de los mismos.
MX2016014515A (es) Composicion topica de crema gel.
MX2015011132A (es) Moduladores policiclicos del receptor de estrogenos y sus usos.
PH12019502692A1 (en) Anti-cancer combination therapy
SG10201908839QA (en) 2,4-dihydroxy-nicotinamides as apj agonists
BR112016018062A8 (pt) compostos terapêuticos, composição farmacêutica e usos
SG11202007860XA (en) Pharmaceutical composition comprising timolol
MX2018015125A (es) Nuevos compuestos antibacterianos.
PH12015502523A1 (en) Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
AU2016380190A8 (en) Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof
EP4331622A3 (en) Integrin binding peptides and uses thereof
MX2017008390A (es) Uretanos funcionalizados con alcoxisilano y funcionalizados con alofanato.
WO2020123753A3 (en) Anellosomes for delivering intracellular therapeutic modalities
AU2018279184A1 (en) Anti-TrkB antibodies
TN2018000057A1 (en) Compounds useful for inhibiting ror-gamma-t.
IL277649A (en) Preparations for the treatment of cancer by combining active substances
MX2024003785A (es) Inhibidor de inmunosupresion asociado al cancer.
EP3875091A4 (en) Pharmaceutical composition containing antitumor agent